Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...

There may be an effective new treatment for people with bladder cancer that doesn't respond to a frontline therapy.

There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report.

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of ...

An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer ...

Grivas said that in the localized bladder cancer setting, he examined data from the CheckMate ... The NIAGARA trial combined ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.

About Bladder Cancer More than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly ...

Like so many others in the community and around the world, the Sault’s Ryan London is bravely battling cancer. In London’s ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...

Durvalumab (Imfinzi) has received Priority Review from the FDA for muscle-invasive bladder cancer (MIBC). Backed by positive ...